Drugs Made In America Acquisition Corp. Rights (DMAAR) Stock Price
Drugs Made In America Acquisition Corp. Rights (NASDAQ: DMAAR) last traded at $0.147, up 2.15% on the session. The quote above updates while this page is open; the figures below are drawn from Drugs Made In America Acquisition Corp. Rights’s own filings and are restated only when a new one is published.
Drugs Made In America Acquisition Corp. Rights (DMAAR) company overview
Drugs Made In America Acquisition Corp. Rights trades on NASDAQ under the ticker DMAAR. Its market capitalisation is $3.58 million.
DMAAR valuation
Valuation measures for Drugs Made In America Acquisition Corp. Rights, derived from the latest quote and its most recent SEC filing.
Market cap
$3.58M
Enterprise value
$12.70M
DMAAR financials
Trailing-twelve-month figures tagged in Drugs Made In America Acquisition Corp. Rights's XBRL filings with the SEC.
Net income (TTM)
$6.09M
Cash
$20.3K
DMAAR trading statistics
Range and volume for DMAAR over the past 52 weeks.
52-week high
$0.158
52-week low
$0.134
Volume
82.0K
Average volume
82.0K
Previous close
$0.144
Drugs Made In America Acquisition Corp. Rights (DMAAR) FAQs
What is the DMAAR stock price today?
Drugs Made In America Acquisition Corp. Rights (DMAAR) last traded at $0.15, up 2.15% on the session. FurlPay quotes DMAAR from Yahoo Finance and stamps each figure with the exchange time it printed.
What exchange is DMAAR listed on?
Drugs Made In America Acquisition Corp. Rights is listed on NASDAQ under the ticker symbol DMAAR.
What is Drugs Made In America Acquisition Corp. Rights's market cap?
Drugs Made In America Acquisition Corp. Rights has a market capitalisation of $3.58 million, derived from its shares outstanding as reported in its SEC filings and the latest quoted price.
What is DMAAR's 52-week range?
Over the past 52 weeks DMAAR has traded between $0.13 and $0.16.
Data sources
Price, range and volume — Yahoo Finance. Quotes may be delayed; each carries the exchange timestamp it printed with.
Financials and valuation — the company’s own XBRL filings with the U.S. Securities and Exchange Commission (CIK 0002028614), period ending 2026-06-30.
A dash means FurlPay does not have that figure, not that it is zero. Nothing on this page is investment advice or a recommendation to buy or sell any security. Figures are provided for information only and may be delayed or restated.
DMAAR Stock Price & Quote | Drugs Made In America Acquisition Corp. Rights | FurlPay